| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ADMAADMA Biologics, Inc. | 4.16B | 17.50 | 21.60 | 65.15% | 42.87% | 48.57% | 2.64% | 0.24 |
| CVACCureVac N.V. | 1.05B | 4.66 | 6.47 | 8.96% | 37.93% | 33.02% | 7.95% | 0.06 |
| DWTXDogwood Therapeutics, Inc. | 83.24M | 2.80 | -0.22 | -49.37% | 0.24 | |||
| ALGSAligos Therapeutics, Inc. | 44.22M | 8.26 | -0.39 | -74.6% | -32.68% | -120.37% | ||
| INOInovio Pharmaceuticals, Inc. | 108.55M | 1.58 | -0.40 | -73.83% | -592.82% | -115.42% | 0.17 | |
| BRNSBarinthus Biotherapeutics plc | 29.81M | 0.73 | -0.47 | 17.66% | -408% | -89.73% | 0.09 | |
| COCPCocrystal Pharma, Inc. | 15.3M | 1.11 | -0.65 | -126.11% | 0.19 | |||
| KLRSKalaris Therapeutics Inc | 165.7M | 8.86 | -0.76 | -170.84% |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 3.44M | 55.24M | 60.88M | 23.9M | 2.24M | 1.32M |
| Revenue Growth % | - | 15.05% | 0.1% | -0.61% | -0.91% | -0.41% |
| Cost of Goods Sold | 0 | 0 | 1.65M | 3.29M | 3.75M | 4.79M |
| COGS % of Revenue | - | - | 0.03% | 0.14% | 1.67% | 3.62% |
| Gross Profit | 3.44M | 55.24M | 59.22M | 20.61M | -1.51M | -3.47M |
| Gross Margin % | 1% | 1% | 0.97% | 0.86% | -0.67% | -2.62% |
| Gross Profit Growth % | - | 15.05% | 0.07% | -0.65% | -1.07% | -1.3% |
| Operating Expenses | 12.12M | 34.68M | 72.62M | 49.53M | 36.57M | 39.44M |
| OpEx % of Revenue | 3.52% | 0.63% | 1.19% | 2.07% | 16.33% | 29.82% |
| Selling, General & Admin | 4.1M | 6.77M | 17.09M | 16.38M | 23.8M | 9.28M |
| SG&A % of Revenue | 1.19% | 0.12% | 0.28% | 0.69% | 10.63% | 7.01% |
| Research & Development | 8.02M | 27.91M | 57.18M | 36.44M | 16.52M | 30.16M |
| R&D % of Revenue | 2.33% | 0.51% | 0.94% | 1.52% | 7.38% | 22.81% |
| Other Operating Expenses | -1K | 0 | -1.65M | -3.29M | -3.75M | 0 |
| Operating Income | -8.67M | 20.56M | -13.39M | -28.92M | -38.08M | -42.91M |
| Operating Margin % | -2.52% | 0.37% | -0.22% | -1.21% | -17.01% | -32.45% |
| Operating Income Growth % | - | 3.37% | -1.65% | -1.16% | -0.32% | -0.13% |
| EBITDA | -8.35M | 21.11M | -11.74M | -25.63M | -34.33M | -38.12M |
| EBITDA Margin % | -2.43% | 0.38% | -0.19% | -1.07% | -15.33% | -28.82% |
| EBITDA Growth % | - | 3.53% | -1.56% | -1.18% | -0.34% | -0.11% |
| D&A (Non-Cash Add-back) | 323.41K | 548.18K | 1.65M | 3.29M | 3.75M | 4.79M |
| EBIT | -8.56M | 20.59M | -16.85M | -18.41M | -41.88M | -33.79M |
| Net Interest Income | -315K | -443K | -271K | -231K | 269.68K | 967.6K |
| Interest Income | 113.13K | 26.13K | 23.11K | 71.07K | 584.97K | 1.29M |
| Interest Expense | 428.48K | 469.15K | 294.46K | 301.58K | 315.28K | 318.4K |
| Other Income/Expense | -313K | -439K | -3.75M | 10.2M | -4.12M | 8.81M |
| Pretax Income | -8.99M | 20.12M | -17.14M | -18.72M | -42.19M | -34.11M |
| Pretax Margin % | -2.61% | 0.36% | -0.28% | -0.78% | -18.85% | -25.79% |
| Income Tax | 0 | 0 | 0 | 25.63K | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -8.99M | 20.12M | -17.14M | -18.74M | -42.19M | -34.11M |
| Net Margin % | -2.61% | 0.36% | -0.28% | -0.78% | -18.85% | -25.79% |
| Net Income Growth % | - | 3.24% | -1.85% | -0.09% | -1.25% | 0.19% |
| Net Income (Continuing) | -8.99M | 20.12M | -17.14M | -18.74M | -42.19M | -34.11M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.22 | 7.45 | -6.30 | -4.31 | -7.64 | -3.68 |
| EPS Growth % | - | 34.86% | -1.85% | 0.32% | -0.77% | 0.52% |
| EPS (Basic) | -0.22 | 4.63 | -3.94 | -4.31 | -7.64 | -3.68 |
| Diluted Shares Outstanding | 4.35M | 2.7M | 2.73M | 4.35M | 5.52M | 9.26M |
| Basic Shares Outstanding | 4.35M | 4.35M | 4.35M | 4.35M | 5.52M | 9.26M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 9.29M | 34.46M | 50.19M | 22.1M | 58.91M | 23.79M |
| Cash & Short-Term Investments | 6.35M | 12.61M | 33.21M | 15.05M | 56.57M | 20.76M |
| Cash Only | 6.35M | 12.61M | 33.21M | 15.05M | 56.57M | 8.9M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 11.86M |
| Accounts Receivable | 2.82M | 20.57M | 8.01M | 5.56M | 0 | 54.95K |
| Days Sales Outstanding | 298.91 | 135.92 | 48.03 | 84.85 | - | 15.17 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 6.34M | 0 | 0 | 2.98M |
| Total Non-Current Assets | 8.71M | 22.08M | 30.95M | 28.81M | 25.03M | 20.4M |
| Property, Plant & Equipment | 8.71M | 22.08M | 30.95M | 28.34M | 24.68M | 19.92M |
| Fixed Asset Turnover | 0.39x | 2.50x | 1.97x | 0.84x | 0.09x | 0.07x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 467.69K | 350.23K | 482.1K |
| Total Assets | 18M | 56.54M | 81.14M | 50.9M | 83.94M | 44.2M |
| Asset Turnover | 0.19x | 0.98x | 0.75x | 0.47x | 0.03x | 0.03x |
| Asset Growth % | - | 2.14% | 0.44% | -0.37% | 0.65% | -0.47% |
| Total Current Liabilities | 4.62M | 11.06M | 26.46M | 14.99M | 10.81M | 7.98M |
| Accounts Payable | 2.17M | 7.38M | 4.46M | 3.68M | 945.93K | 1.69M |
| Days Payables Outstanding | - | - | 983.89 | 407.92 | 92.19 | 129.07 |
| Short-Term Debt | 1.39M | 538.73K | 1.8M | 772.66K | 1.05M | 811.84K |
| Deferred Revenue (Current) | 0 | 100K | 100K | 0 | 1000K | 0 |
| Other Current Liabilities | 248.72K | 1.17M | 8.7M | 8.1M | 4.49M | 5.47M |
| Current Ratio | 2.01x | 3.11x | 1.90x | 1.47x | 5.45x | 2.98x |
| Quick Ratio | 2.01x | 3.11x | 1.90x | 1.47x | 5.45x | 2.98x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 15.69M | 6.47M | 16.14M | 4.85M | 15.83M | 10.25M |
| Long-Term Debt | 53.45K | 172.04K | 0 | 541.64K | 0 | 0 |
| Capital Lease Obligations | 5.64M | 6.3M | 5.42M | 3.99M | 4.05M | 3.86M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 10M | 0 | 10.72M | 320.93K | 11.77M | 6.39M |
| Total Liabilities | 20.31M | 17.53M | 42.59M | 19.85M | 26.64M | 18.23M |
| Total Debt | 7.64M | 8.13M | 8.52M | 5.93M | 5.91M | 4.67M |
| Net Debt | 1.29M | -4.48M | -24.69M | -9.12M | -50.66M | -4.23M |
| Debt / Equity | - | 0.21x | 0.22x | 0.19x | 0.10x | 0.18x |
| Debt / EBITDA | - | 0.39x | - | - | - | - |
| Net Debt / EBITDA | - | -0.21x | - | - | - | - |
| Interest Coverage | -20.24x | 43.82x | -45.48x | -95.89x | -120.76x | -134.77x |
| Total Equity | -2.31M | 39.01M | 38.55M | 31.06M | 57.3M | 25.97M |
| Equity Growth % | - | 17.92% | -0.01% | -0.19% | 0.84% | -0.55% |
| Book Value per Share | -0.53 | 14.44 | 14.10 | 7.14 | 10.38 | 2.80 |
| Total Shareholders' Equity | -2.31M | 39.01M | 38.55M | 31.06M | 57.3M | 25.97M |
| Common Stock | 3.52K | 3.52K | 4.35K | 5.09K | 929 | 935 |
| Retained Earnings | -32.1M | -11.98M | -29.13M | -47.87M | -90.06M | -124.17M |
| Treasury Stock | 0 | 0 | 0 | -5.52M | -5.52M | -5.52M |
| Accumulated OCI | 0 | 0 | 0 | 0 | 26.42K | -135.41K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -9.21M | 10M | 1.99M | -23.46M | -25.12M | -34.29M |
| Operating CF Margin % | -2.68% | 0.18% | 0.03% | -0.98% | -11.22% | -25.93% |
| Operating CF Growth % | - | 2.09% | -0.8% | -12.81% | -0.07% | -0.37% |
| Net Income | -8.99M | 20.12M | -17.14M | -18.74M | -42.19M | -34.11M |
| Depreciation & Amortization | 323.41K | 548.18K | 1.65M | 3.29M | 3.75M | 4.79M |
| Stock-Based Compensation | 371.39K | 1.3M | 0 | 2.67M | 2.42M | 2.94M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 422 | -2.25K | 5.79M | -10.45M | 8.58M | -5.62M |
| Working Capital Changes | -923.37K | -11.95M | 11.68M | -237.57K | 2.33M | -2.3M |
| Change in Receivables | -2.56M | -17.75M | 12.56M | 2.45M | 5.56M | -54.95K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.56M | 5.21M | -2.94M | -779.42K | -2.7M | 923.32K |
| Cash from Investing | -608.75K | -12.72M | -10.94M | -2.09M | -152.7K | -11.96M |
| Capital Expenditures | -608.75K | -12.73M | -10.94M | -2.17M | -197.15K | -337.26K |
| CapEx % of Revenue | 0.18% | 0.23% | 0.18% | 0.09% | 0.09% | 0.26% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 9K | 0 | 76.39K | 44.45K | 0 |
| Cash from Financing | 3.68M | 8.98M | 35.89M | 1.05M | 66.77M | -1.17M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 0 | -9.9M | 34.34M | 76.97K | 59.66M | -286.04K |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -9.82M | -2.73M | -8.96M | -25.63M | -25.32M | -34.63M |
| FCF Margin % | -2.85% | -0.05% | -0.15% | -1.07% | -11.31% | -26.19% |
| FCF Growth % | - | 0.72% | -2.28% | -1.86% | 0.01% | -0.37% |
| FCF per Share | -2.26 | -1.01 | -3.28 | -5.89 | -4.59 | -3.74 |
| FCF Conversion (FCF/Net Income) | 1.03x | 0.50x | -0.12x | 1.25x | 0.60x | 1.01x |
| Interest Paid | 428.48K | 469.15K | 0 | 293.39K | 245.48K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | 109.63% | -44.21% | -53.85% | -95.51% | -81.92% |
| Return on Invested Capital (ROIC) | - | 92.02% | -41.52% | -121.17% | -199.83% | -226.79% |
| Gross Margin | 100% | 100% | 97.28% | 86.23% | -67.26% | -262.41% |
| Net Margin | -261.07% | 36.42% | -28.16% | -78.4% | -1884.5% | -2579.03% |
| Debt / Equity | - | 0.21x | 0.22x | 0.19x | 0.10x | 0.18x |
| Interest Coverage | -20.24x | 43.82x | -45.48x | -95.89x | -120.76x | -134.77x |
| FCF Conversion | 1.03x | 0.50x | -0.12x | 1.25x | 0.60x | 1.01x |
| Revenue Growth | - | 1504.82% | 10.21% | -60.73% | -90.63% | -40.94% |
| 2021 | 2022 | |
|---|---|---|
| Grant | - | 23.9M |
| Grant Growth | - | - |
| Grant Revenue | 60.88M | - |
| Grant Revenue Growth | - | - |
SAB Biotherapeutics, Inc. (SABS) reported $0.1M in revenue for fiscal year 2024. This represents a 97% decrease from $3.4M in 2019.
SAB Biotherapeutics, Inc. (SABS) saw revenue decline by 40.9% over the past year.
SAB Biotherapeutics, Inc. (SABS) reported a net loss of $21.4M for fiscal year 2024.
SAB Biotherapeutics, Inc. (SABS) has a return on equity (ROE) of -81.9%. Negative ROE indicates the company is unprofitable.
SAB Biotherapeutics, Inc. (SABS) had negative free cash flow of $37.3M in fiscal year 2024, likely due to heavy capital investments.